Please provide your email address to receive an email when new articles are posted on . In patients with ACS who had angioplasty and stenting, ticagrelor monotherapy after 1 month reduced bleeding vs.

The Librexia ACS trial was discontinued after an interim analysis showed the study was unlikely to meet its primary endpoint of reducing MACE. The phase 3 Librexia ACS trial evaluating the safety and ...

Bristol Myers BMY announced that it will discontinue the late-stage Librexia study evaluating the efficacy and safety of pipeline candidate milvexian when added to the standard of care (conventional ...

ANAHEIM, CA—International, locally adapted programs to improve the care of patients with acute myocardial infarction seem to be showing promise in a variety of settings, according to two new studies.

Heart failure hospitalisation significantly increases mortality after PCI. Learn why adverse events should not be treated ...